3xtg-ad-mouse

Migration, Crosslink

📖

3xtg-ad-mouse

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-3xtg-ad-mouse

📖 Wiki Page

mechanism2055 wordssynced 2026-04-02

3xtg-ad-mouse

Overview

The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease that expresses three mutant genes associated with familial AD: [APP](/genes/app) Swedish, [MAPT](/genes/mapt) P301L, and [PSEN1](/genes/psen1) M146V. This model, developed by Oddo et al. in 2003, is unique in that it develops both amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), making it a valuable tool for studying AD pathogenesis and the interaction between the two hallmark pathologies[@oddo2003].

The 3xTG-AD model has become one of the most widely used animal models for AD research due to its ability to reproduce both major pathological hallmarks of the disease in a temporal pattern that roughly mirrors human disease progression. Researchers have utilized this model to investigate disease mechanisms, test therapeutic interventions, and explore the relationship between amyloid and tau pathologies[@querfurth2010].

Genetic Background

Transgenes

The 3xTG-AD model contains three human transgenes driven by neuron-specific promoters[@oddo2003a].

| Gene | Mutation | Promoter | Effect |
|------|----------|----------|--------|
| [APP](/genes/app) | Swedish (KM670/671NL) | Thy1.2 | Increased Aβ production |
| [MAPT](/genes/mapt) (Tau) | P301L | Thy1.2 | Tau aggregation |
| [PSEN1](/genes/psen1) | M146V | Endogenous (knock-in) | Altered γ-secretase |

APP Swedish Mutation

...

3xtg-ad-mouse

Overview

The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease that expresses three mutant genes associated with familial AD: [APP](/genes/app) Swedish, [MAPT](/genes/mapt) P301L, and [PSEN1](/genes/psen1) M146V. This model, developed by Oddo et al. in 2003, is unique in that it develops both amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), making it a valuable tool for studying AD pathogenesis and the interaction between the two hallmark pathologies[@oddo2003].

The 3xTG-AD model has become one of the most widely used animal models for AD research due to its ability to reproduce both major pathological hallmarks of the disease in a temporal pattern that roughly mirrors human disease progression. Researchers have utilized this model to investigate disease mechanisms, test therapeutic interventions, and explore the relationship between amyloid and tau pathologies[@querfurth2010].

Genetic Background

Transgenes

The 3xTG-AD model contains three human transgenes driven by neuron-specific promoters[@oddo2003a].

| Gene | Mutation | Promoter | Effect |
|------|----------|----------|--------|
| [APP](/genes/app) | Swedish (KM670/671NL) | Thy1.2 | Increased Aβ production |
| [MAPT](/genes/mapt) (Tau) | P301L | Thy1.2 | Tau aggregation |
| [PSEN1](/genes/psen1) | M146V | Endogenous (knock-in) | Altered γ-secretase |

APP Swedish Mutation

The Swedish double mutation (K670N/M671L) in the [APP](/genes/app) gene was originally identified in a Swedish family with early-onset familial AD. This mutation is located at the β-secretase cleavage site and increases amyloid-beta production by 3-4 fold, particularly increasing the more aggregation-prone Aβ₁₋₄₂ species. The Thy1.2 promoter drives neuron-specific expression, leading to accumulation of Aβ primarily in the brain rather than peripheral tissues[@oddo2003].

MAPT P301L Mutation

The P301L tau mutation in [MAPT](/genes/mapt) is associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). This mutation promotes hyperphosphorylation and aggregation of tau into neurofibrillary tangles by reducing microtubule binding affinity. In the 3xTG-AD model, tau pathology develops progressively with age, first appearing in the hippocampus and then spreading to cortical regions[@oddo2004].

PSEN1 M146V Mutation

The M146V presenilin-1 mutation in [PSEN1](/genes/psen1) is a familial AD mutation that enhances γ-secretase activity, leading to increased Aβ₁₋₄₂ production. The mutation is knocked into the endogenous mouse Psen1 locus, ensuring physiologically appropriate expression levels. This knock-in approach prevents the overexpression artifacts that can occur with transgenic constructs[@laferla2012].

Background Strain

Strain: C57BL6/129S mixed background
Targeting: Neuron-specific expression via Thy1.2 promoter
Integration: Chromosome integration at unknown locus

Phenotype Characteristics

Amyloid-Beta Plaques

Onset: 6 months of age
Location: Cortex and hippocampus
Progression: Increases dramatically with age
Type: Mixed Aβ40 and Aβ42, with Aβ42 predominating
Pattern: Follows a pattern reminiscent of human AD progression

The amyloid pathology in 3xTG-AD mice follows a defined temporal progression. At 6 months, diffuse Aβ deposits appear in the subiculum and cortex. By 12 months, plaque density increases significantly throughout the hippocampus and cortex. The plaques are primarily composed of Aβ₁₋₄₂ with some Aβ₁₋₄₀, matching the human AD pattern where Aβ₄₂ initiates aggregation[@oddo2004].

Neurofibrillary Tangles

Onset: 12-15 months of age
Location: Hippocampus and cortex
Progression: Progressive with age
Form: Hyperphosphorylated tau aggregates at multiple epitopes (AT8, AT180, PHF-1)

Tau pathology develops after Aβ pathology, consistent with the amyloid cascade hypothesis. The P301L mutation promotes aggregation, but true neurofibrillary tangles are limited by species differences in tau sequence. The model shows phosphorylated tau at multiple epitopes, including AT8 (Ser202/Thr205), AT180 (Thr231), and PHF-1 (Ser396/404)[@hansson2019].

Synaptic Deficits

Early deficits: Observed before plaque/tangle formation (by 3-4 months)
Synaptic plasticity: Impaired long-term potentiation (LTP) in hippocampal CA1
Structural changes: Reduced dendritic spine density
Cognitive decline: Spatial memory deficits evident at 6-12 months

Synaptic dysfunction is one of the earliest measurable deficits in the 3xTG-AD model. Electrophysiological studies reveal impaired LTP in the hippocampal CA1 region as early as 3-4 months, before the appearance of Aβ plaques or tau tangles. This early synaptic impairment is thought to result from soluble Aβ oligomers that accumulate intracellularly and disrupt synaptic function[@billings2005][@singh2015].

Behavioral Phenotype

Spatial memory: Impaired in Morris water maze (by 6 months)
Working memory: Deficits in Y-maze tasks
Anxiety-like behavior: Changes in elevated plus-maze
Progressive decline: Worsens with age

Cognitive deficits in 3xTG-AD mice develop in an age-dependent manner. At 6 months, mice show impaired performance in the Morris water maze, particularly in the reversal learning phase. Y-maze testing reveals working memory deficits by 9 months. Anxiety-like behavior is often reduced, possibly reflecting limbic system involvement[@gimenez2009].

Neuroinflammation

Microglial Activation

The 3xTG-AD model exhibits robust neuroinflammation, with microglial activation accompanying Aβ and tau pathology. Activated microglia cluster around Aβ plaques, adopting a disease-associated microglia (DAM) phenotype. These microglia attempt to clear Aβ through phagocytosis but may become dysfunctional, contributing to chronic inflammation[@le2014].

Microglial activation can be detected using Iba1 immunohistochemistry, with increased staining density around plaques and in regions of tau pathology. The inflammatory response includes production of cytokines such as IL-1β, TNF-α, and IL-6, which may contribute to synaptic dysfunction and disease progression.

Astrocytosis

Reactive astrocytes are also prominent in the 3xTG-AD model. GFAP-positive astrocytes show hypertrophy and increased proliferation in response to neuropathology. Astrocytic responses include both potentially beneficial functions (Aβ sequestration, neurotrophic support) and detrimental effects (excitotoxicity, inflammatory mediator release)[@rodriguez2013].

Metabolic Dysfunction

Mitochondrial Abnormalities

The 3xTG-AD model demonstrates significant mitochondrial dysfunction. Proteomic studies have identified altered expression of mitochondrial proteins involved in energy metabolism, oxidative phosphorylation, and antioxidant defenses. These changes precede visible pathology and may contribute to neuronal vulnerability[@perez2005][@bai2020].

Complex I and IV activity is reduced in aged 3xTG-AD mice, leading to impaired ATP production. This energy deficit is particularly pronounced in hippocampus and cortex, the regions most affected by Aβ and tau pathology.

Glucose Hypometabolism

In vivo imaging studies have demonstrated cerebral glucose hypometabolism in the 3xTG-AD model, similar to patterns observed in human AD patients. PET imaging using fluorodeoxyglucose (FDG) shows reduced glucose uptake in the hippocampus and cortex that correlates with cognitive deficits[@yang2018].

Autophagy and Proteostasis

Autophagy Impairment

Autophagy is impaired in the 3xTG-AD model, with accumulation of autophagic vacuoles in neurons. This impairment affects the clearance of both Aβ and tau, contributing to protein aggregation. The mTOR pathway shows dysregulation, and restore of autophagy through pharmacological approaches has shown promise in reducing pathology[@zhang2019].

Lysosomal Dysfunction

Lysosomal cathepsin activity is altered in the 3xTG-AD model, with reduced activity of several hydrolases. This lysosomal dysfunction prevents proper degradation of protein aggregates and contributes to the accumulation of Aβ and tau in intracellular compartments.

Neurogenesis

Adult Hippocampal Neurogenesis

The 3xTG-AD model shows impaired adult hippocampal neurogenesis in the subgranular zone of the dentate gyrus. Reduced proliferation of neural progenitor cells and decreased survival of new neurons contribute to cognitive deficits. This impairment may be mediated by Aβ toxicity and inflammatory changes in the neurogenic niche[@mu2020].

Comparison to Other AD Models

3xTG-AD vs APP/PS1

| Feature | 3xTG-AD | APP/PS1 |
|---------|----------|----------|
| Amyloid plaques | Yes | Yes |
| Neurofibrillary tangles | Yes | No |
| Tau pathology | Yes | No |
| Onset (plaques) | 6 months | 6-9 months |
| Dual pathology | Yes | No |

3xTG-AD vs Tg2576

| Feature | 3xTG-AD | Tg2576 |
|---------|----------|--------|
| Mutation | APP Swedish + Tau + PS1 | APP Swedish only |
| Plaques | Yes | Yes |
| Tangles | Yes | No |
| Cognitive deficits | More severe | Moderate |
| Age of onset | 6 months | 9-12 months |

3xTG-AD vs 5XFAD

| Feature | 3xTG-AD | 5XFAD |
|---------|----------|-------|
| APP mutations | 1 (Swedish) | 3 (Swedish, Florida, London) |
| PSEN1 mutations | 1 (M146V) | 1 (L383) |
| Tau mutation | Yes (P301L) | No |
| Plaque onset | 6 months | 2 months |
| Tangle formation | Yes | Minimal |

Research Applications

Therapeutic Testing

The 3xTG-AD model is widely used to test[@laferla2012]:

Anti-amyloid therapies: Immunotherapies (anti-Aβ antibodies), secretase modulators

Anti-tau therapies: Tau aggregation inhibitors, kinase inhibitors, immunotherapy

Combination approaches: Simultaneous Aβ and tau targeting

Disease-modifying interventions: Testing interventions that modify disease progression

The dual pathology of the 3xTG-AD model makes it particularly valuable for testing therapies that target both Aβ and tau, which is thought to be necessary for meaningful disease modification in human AD.

Disease Mechanism Studies

Amyloid-tau interaction: Cross-seeding and templated propagation studies
Temporal relationships: Determining which pathology drives progression
Propagation mechanisms: Spreading of pathology through neural circuits
Synaptic dysfunction: Early events preceding visible pathology

Studies using the 3xTG-AD model have demonstrated that Aβ pathology can accelerate tau propagation, supporting the hypothesis that Aβ drives downstream tau pathology[@pooler2012].

Biomarker Development

Fluid biomarkers: CSF Aβ and tau correlation with brain pathology
Imaging biomarkers: PET amyloid and tau binding
Behavioral correlations: Test performance correlates with neuropathology

The 3xTG-AD model has been instrumental in validating CSF and imaging biomarkers that translate between preclinical studies and human clinical trials.

Therapeutic Pipeline

The model has been used to test numerous therapeutic approaches:

Immunotherapies: Both active (Aβ vaccines) and passive (monoclonal antibody) approaches
Small molecule inhibitors: BACE inhibitors, γ-secretase modulators
Tau-targeted therapies: Anti-tau antibodies, aggregation inhibitors
Regenerative approaches: Stem cell therapy, neurotrophic factors

Strengths

Dual pathology: Both Aβ and tau pathology in one model
Age-dependent progression: Clear temporal progression of pathologies
Behavioral deficits: Reproducible cognitive impairment
Synaptic pathology: Early synaptic dysfunction before plaques/tangles
Cross-seeding studies: Unique ability to study Aβ-tau interactions
Therapeutic testing: Comprehensive platform for combination therapies

Limitations

Strain variability: Genetic background affects phenotype expression
Non-physiological expression: Thy1.2 promoter drives higher than normal levels
Translation concerns: Murine model cannot fully replicate human AD
Tau pathology: Less robust neurofibrillary tangles than in human AD
Species differences: Mouse tau does not form true human-style NFTs
Glial differences: Murine glial responses may differ from human

Experimental Considerations

Breeding and Maintenance

The 3xTG-AD colony requires careful genetic monitoring. Regular genotyping is essential to maintain the triple transgenic status. The model can be maintained as homozygous or heterozygous breeding, with homozygous breeders producing more consistent phenotypes but requiring more intensive colony management.

Behavioral Testing Protocols

Standardized behavioral testing protocols have been developed for the 3xTG-AD model. The recommended battery includes:

Morris water maze: Spatial learning and memory (6+ months)
Y-maze: Working memory (6+ months)
Elevated plus-maze: Anxiety-like behavior
Novel object recognition: Episodic memory
Contextual fear conditioning: Associative learning

Histological Protocols

Recommended immunohistochemistry for pathological assessment:

Aβ plaques: 6E10, 4G8, Thioflavin S
Tau pathology: AT8, AT180, PHF-1, MC1
Microglia: Iba1, CD68
Astrocytes: GFAP
Synapses: Synaptophysin, PSD-95

Key Publications

[Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles. Neuron. 2003](https://doi.org/10.1016/s0896-6273(03)00434-3)[@oddo2003]

[Oddo S, Caccamo A, Kitazawa M, et al. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003](https://doi.org/10.1016/j.neurobiolaging.2003.08.012)[@oddo2003a]

[LaFerla FM, Green KN. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med. 2012](https://doi.org/10.1101/cshperspect.a006320)[@laferla2012]

[Oddo S, Caccamo A, Smith IF, et al. Dynamic changes in Aβ and tau pathology in the 3xTG-AD model. J Neurosci. 2004](https://doi.org/10.1523/jneurosci.1630-04.2004)[@oddo2004]

[Billings LM, Oddo S, Green KN, et al. Intraneuronal Aβ causes the onset of early AD-related cognitive deficits. Neuron. 2005](https://doi.org/10.1016/j.neuron.2005.01.010)[@billings2005]

[Giménez-Llort L, et al. Modeling key features of Alzheimer's disease in 3xTG-AD mice. Int J Alzheimer's Dis. 2009](https://doi.org/10.4061/2009/457864)[@gimenez2009]

[Le MY, et al. Neuroinflammation in the 3xTG-AD model. J Neuroinflammation. 2014](https://doi.org/10.1186/s12974-014-0165-8)[@le2014]

[Rodriguez JJ, et al. Glial responses in the 3xTG-AD model. Prog Neuropsychopharmacol Biol Psychiatry. 2013](https://doi.org/10.1016/j.pnpbp.2012.10.017)[@rodriguez2013]

[Pooler AM, et al. Amyloid accelerates tau propagation in the 3xTG-AD model. J Neurosci. 2012](https://doi.org/10.1523/jneurosci.4261-12.2012)[@pooler2012]

[Singh V, et al. Synaptic deficits in the 3xTG-AD model. Neurobiol Aging. 2015](https://doi.org/10.1016/j.neurobiolaging.2015.01.010)[@singh2015]

[Hansson O, et al. Tau pathology and neurodegeneration in the 3xTG-AD model. Brain Pathol. 2019](https://doi.org/10.1111/bpa.12667)[@hansson2019]

[Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010](https://doi.org/10.1056/nejmra0909142)[@querfurth2010]

slug	mechanisms-3xtg-ad-mouse
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-50c3bd134cf5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-3xtg-ad-mouse'}
_schema_version	1

📗 Cite This Artifact

3xtg-ad-mouse

3xtg-ad-mouse

Overview

Genetic Background

Transgenes

APP Swedish Mutation

3xtg-ad-mouse

Overview

Genetic Background

Transgenes

APP Swedish Mutation

MAPT P301L Mutation

PSEN1 M146V Mutation

Background Strain

Phenotype Characteristics

Amyloid-Beta Plaques

Neurofibrillary Tangles

Synaptic Deficits

Behavioral Phenotype

Neuroinflammation

Microglial Activation

Astrocytosis

Metabolic Dysfunction

Mitochondrial Abnormalities

Glucose Hypometabolism

Autophagy and Proteostasis

Autophagy Impairment

Lysosomal Dysfunction

Neurogenesis

Adult Hippocampal Neurogenesis

Comparison to Other AD Models

3xTG-AD vs APP/PS1

3xTG-AD vs Tg2576

3xTG-AD vs 5XFAD

Research Applications

Therapeutic Testing

Disease Mechanism Studies

Biomarker Development

Therapeutic Pipeline

Strengths

Limitations

Experimental Considerations

Breeding and Maintenance

Behavioral Testing Protocols

Histological Protocols

Key Publications

See Also

💬 Discussion